These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21982383)

  • 41. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.
    Suzuki F; Toyota J; Ikeda K; Chayama K; Mochida S; Hayashi N; Ishikawa H; Miyagoshi H; Hu W; McPhee F; Hughes EA; Kumada H
    Antivir Ther; 2014; 19(5):491-9. PubMed ID: 24451122
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.
    Swain MG; Lai MY; Shiffman ML; Cooksley WG; Zeuzem S; Dieterich DT; Abergel A; Pessôa MG; Lin A; Tietz A; Connell EV; Diago M
    Gastroenterology; 2010 Nov; 139(5):1593-601. PubMed ID: 20637202
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels.
    Calleja JL; García-Samaniego J; Ruiz-Antorán B; Trapero M; Morillas R; de la Revilla J; Erdozaín JC; Espinosa MD; Suárez D; Solá R; Romero-Gómez M; Baños F; Alvarez MA;
    J Gastroenterol Hepatol; 2012 Nov; 27(11):1705-10. PubMed ID: 22742958
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for hepatitis C infection.
    Mahajan S; Avasthi A; Grover S; Chawla YK
    J Psychosom Res; 2014 Aug; 77(2):109-15. PubMed ID: 25077851
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.
    Fernández-Rodríguez CM; Morillas RM; Masnou H; Navarro JM; Bárcena R; González JM; Martín-Martín L; Poyato A; Miquel-Planas M; Jorquera F; Casanovas T; Salmerón J; Calleja JL; Solà R; Alonso S; Planas R; Romero-Gomez M
    Gastroenterol Hepatol; 2014 Jan; 37(1):1-8. PubMed ID: 24360571
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
    Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA
    Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
    Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
    Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
    Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A
    Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin.
    Santantonio T; Fasano M; Sagnelli E; Tundo P; Babudieri S; Fabris P; Toti M; Di Perri G; Marino N; Pizzigallo E; Angarano G;
    Hepatology; 2014 Jun; 59(6):2101-9. PubMed ID: 24442928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
    Marcellin P; Cooper C; Balart L; Larrey D; Box T; Yoshida E; Lawitz E; Buggisch P; Ferenci P; Weltman M; Labriola-Tompkins E; Le Pogam S; Nájera I; Thomas D; Hooper G; Shulman NS; Zhang Y; Navarro MT; Lim CY; Brunda M; Terrault NA; Yetzer ES
    Gastroenterology; 2013 Oct; 145(4):790-800.e3. PubMed ID: 23811112
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
    Yu ML; Dai CY; Huang JF; Hou NJ; Lee LP; Hsieh MY; Chiu CF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Gut; 2007 Apr; 56(4):553-9. PubMed ID: 16956917
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection.
    Alavi M; Grebely J; Matthews GV; Petoumenos K; Yeung B; Day C; Lloyd AR; Van Beek I; Kaldor JM; Hellard M; Dore GJ; Haber PS;
    J Gastroenterol Hepatol; 2012 May; 27(5):957-65. PubMed ID: 22142332
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment.
    Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
    Int J Infect Dis; 2011 Nov; 15(11):e740-6. PubMed ID: 21803628
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a.
    Zhou YQ; Wang XH; Hong GH; Zhu Y; Zhang XQ; Hu YJ; Mao Q
    J Viral Hepat; 2011 Aug; 18(8):595-600. PubMed ID: 21105968
    [TBL] [Abstract][Full Text] [Related]  

  • 55. "Hepatitis C (HCV) treatment is not a "one size fits all".
    Bukeirat FA; Bukeirat MM
    W V Med J; 2012; 108(2):20, 22-4. PubMed ID: 22655431
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN.
    Vabo IL; Ferreira LE; Pace FH
    Arq Gastroenterol; 2016; 53(1):20-4. PubMed ID: 27281500
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients.
    Feng B; Zhang W; Luo BF; Song GJ; Wang J; Jin Q; Qin H; Wei L
    World J Gastroenterol; 2014 Nov; 20(41):15387-97. PubMed ID: 25386089
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Emerging treatments for hepatitis C.
    Flisiak R; Jaroszewicz J; Parfieniuk-Kowerda A
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):461-75. PubMed ID: 24102413
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduction in neutrophil count during hepatitis C treatment: drug toxicity or predictor of good response?
    Alvarez-Uria G; Day JN; Nasir AJ; Russell SK; Vilar FJ
    Dig Dis Sci; 2010 Jul; 55(7):2058-62. PubMed ID: 19757045
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increased hope following successful treatment for hepatitis C infection.
    Bjøro B; Dalgard O; Midgard H; Verbaan H; Småstuen MC; Rustøen T
    J Adv Nurs; 2018 Mar; 74(3):724-733. PubMed ID: 29082540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.